PMID- 28669026
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2193-8245 (Print)
IS  - 2193-6528 (Electronic)
VI  - 6
IP  - 2
DP  - 2017 Dec
TI  - A Pilot Study on Ocular Safety and Efficacy of Infliximab as an Antifibrotic 
      Agent After Experimental Glaucoma Filtration Surgery.
PG  - 323-334
LID - 10.1007/s40123-017-0096-4 [doi]
AB  - INTRODUCTION: Tumor necrosis factor-alpha (TNF-alpha) is a multifunctional, 
      proinflammatory cytokine that mediates pleiotropic biological functions, 
      especially inflammation and immunoregulation. We hypothesized that blocking TNF-alpha 
      with a monoclonal antibody would decrease inflammation and subconjunctival 
      scarring in an animal model of experimental filtration surgery. METHODS: In a 
      randomized, prospective, masked-observer study, 30 New Zealand albino rabbits 
      underwent glaucoma filtration surgery. The animals were allocated to receive 
      either intraoperative application of infliximab (group A) or mitomycin C (MMC) at 
      a concentration of 0.2 mg/ml (group B) or balanced salt solution (BSS, control) 
      (group C). Different infliximab doses, namely 1.0, 2.0, 3.0, 4.0, 5.0 mg in 
      0.1 ml, were applied. Bleb survival and characteristics were evaluated over a 
      30-day period. The animals were killed on postoperative day 15 or 30. Histology 
      of the operated eyes was performed to evaluate and grade the amount of scarring 
      in each group. Cellular density was evaluated in each case. RESULTS: Infliximab 
      did not appear to improve outcomes in this model of glaucoma filtration surgery. 
      Bleb survival was significantly higher in the MMC group compared to the other 
      groups (p < 0.001 for both comparisons). Vascularity was also significantly lower 
      in the MMC group compared to the other groups (p = 0.018 for both comparisons). 
      There was a significant decrease in cellular density in the MMC group compared to 
      the control (p = 0.0352) and the infliximab group (p < 001). CONCLUSION: Our 
      results have shown that trabeculectomies in the infliximab group failed faster 
      and displayed more scarring, compared to the control and MMC groups. This outcome 
      suggests that the infliximab doses used in this pilot study resulted in a 
      subconjunctival TNF-alpha concentration, which acted as a stimulator to fibroblasts.
FAU - Nikita, Eleni
AU  - Nikita E
AUID- ORCID: 0000-0003-2761-390X
AD  - Attikon University Hospital, Athens, Greece. elenikita@hotmail.co.uk.
FAU - Moulin, Alexandre
AU  - Moulin A
AD  - Jules Gonin Eye Hospital, Lausanne, Switzerland.
FAU - Vergados, Ioannis
AU  - Vergados I
AD  - Attikon University Hospital, Athens, Greece.
FAU - Brouzas, Dimitrios
AU  - Brouzas D
AD  - General Hospital of Athens "G Gennimatas", Athens, Greece.
FAU - Theodossiadis, Panagiotis G
AU  - Theodossiadis PG
AD  - Attikon University Hospital, Athens, Greece.
LA  - eng
PT  - Journal Article
DEP - 20170701
PL  - England
TA  - Ophthalmol Ther
JT  - Ophthalmology and therapy
JID - 101634502
PMC - PMC5693834
OTO - NOTNLM
OT  - Infliximab
OT  - Trabeculectomy
OT  - Tumor necrosis factor-alpha
EDAT- 2017/07/03 06:00
MHDA- 2017/07/03 06:01
PMCR- 2017/07/01
CRDT- 2017/07/03 06:00
PHST- 2017/05/17 00:00 [received]
PHST- 2017/07/03 06:00 [pubmed]
PHST- 2017/07/03 06:01 [medline]
PHST- 2017/07/03 06:00 [entrez]
PHST- 2017/07/01 00:00 [pmc-release]
AID - 10.1007/s40123-017-0096-4 [pii]
AID - 96 [pii]
AID - 10.1007/s40123-017-0096-4 [doi]
PST - ppublish
SO  - Ophthalmol Ther. 2017 Dec;6(2):323-334. doi: 10.1007/s40123-017-0096-4. Epub 2017 
      Jul 1.